Alpa Laboratories share news, announcements and annual reports
NSE: ALPABSE: 532878Pharmaceuticals & BiotechnologySmall Cap
Alpa Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2007
Last close ₹50.38down ₹2.24 (4.26%)BSE ₹49.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹52.62.
30 Oct: open ₹51.50, high ₹51.65, low ₹50.00
52-week range of traded prices to 30 Oct 2026
₹46.10Low, 30 Mar 2026₹93.85High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹106 Cr2,659th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.57
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,77166.0% delivered
Alpa Laboratories share news and announcements
363 announcements, routine notices left out, newest first. Page 5 of 8.
Jun 2018
May 2018
28 May · Legal
Exchange has sought clarification from Alpa Laboratories Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not submitted within 30 minutes from end of board meeting. -2. Consolidated audited review report not submitted. -3. Standalone Reconciliation of profit and loss not submitted -4. Standalone Reconciliation of Equity not submitted -5. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. -6. Consolidated Reconciliation of profit and loss not submitted -7. Consolidated Reconciliation of Equity not submitted The response of the Company is awaited.28 May · Results
26 May · Board meeting
Apr 2018
Mar 2018
28 Mar · Board meeting
Feb 2018
13 Feb · Board meeting
12 Feb · Results
Jan 2018
22 Jan · Business
Dec 2017
18 Dec · Legal
Exchange has sought clarification from Alpa Laboratories Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results not submitted as per Schedule III to the Companies Act, 2013 -2. Segment details not submitted The response of the Company is awaited.15 Dec · Results
15 Dec · Board meeting
Nov 2017
Sep 2017
30 Sep · Management
29 Sep · Meeting
9 Sep · Results
Aug 2017
31 Aug · Board meeting
10 Aug · Board meeting
Jul 2017
Jun 2017
8 Jun · Declaration for audit reports with unmodified opinion(s)
May 2017
29 May · Results
Apr 2017
Mar 2017
Feb 2017
6 Feb · Results
Jan 2017
Nov 2016
12 Nov · Results
Oct 2016
3 Oct · Regulation 44(3) of SEBI (LODR), Reg., 2015
Sep 2016
Aug 2016
Jul 2016
23 Jul · Updates